A prospective, open-label and parallel non-randomized control trial and biomarker research study is intended to compare incidence of repeated COVID-19 infection, severe pneumonitis and mortality between lung cancer patients undergoing systemic antitumor therapies who get vaccinated with 1 booster dose(majorly against XBB) and those who refuse. Meanwhile, a biomarker research is designed to monitor serum level dynamics of specific antibodies against COVID-19,analyze its correlation with incidence of breakthrough infection and further explore optimal periods for vaccination.
Patients who agree to participate in the trial and sign the informed consents.
Male or female, ≥18 years old.
Diagnosed of lung carcinoma by histological and cytological examinations.
Undergoing systemic anti-tumor treatments including chemotherapy, immunotherapy, chemoimmunotherapy and targeted therapy.
Life expectance less than 3 months.
Less than 3 months since last confirmed COVID-19 infection.
Patients unable to return the hospital for follow-up.
Patients allergic to COVID-19 vaccine.